142 related articles for article (PubMed ID: 10459148)
1. Selection of genetic variants of the 5' noncoding region of hepatitis C virus occurs only in patients responding to interferon alpha therapy.
Lu M; Wiese M; Roggendorf M
J Med Virol; 1999 Oct; 59(2):146-53. PubMed ID: 10459148
[TBL] [Abstract][Full Text] [Related]
2. Different susceptibilities of genetic variants of hepatitis C virus (HCV) to interferon (IFN).
Lu M; Wiese M; Funsch B; Roggendorf M
Arch Virol; 1997; 142(3):581-8. PubMed ID: 9349304
[TBL] [Abstract][Full Text] [Related]
3. Secondary structure of the hepatitis C virus 5' untranslated region and efficacy of interferon therapy for chronic hepatitis C.
Suzuki K; Shinzawa H; Kuboki M; Ishibashi M; Yoshii E; Saito T; Takahashi T
Liver; 1998 Oct; 18(5):331-6. PubMed ID: 9831362
[TBL] [Abstract][Full Text] [Related]
4. Quasispecies heterogeneity and constraints on the evolution of the 5' noncoding region of hepatitis C virus (HCV): relationship with HCV resistance to interferon-alpha therapy.
Soler M; Pellerin M; Malnou CE; Dhumeaux D; Kean KM; Pawlotsky JM
Virology; 2002 Jun; 298(1):160-73. PubMed ID: 12093183
[TBL] [Abstract][Full Text] [Related]
5. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.
Sandres K; Dubois M; Pasquier C; Payen JL; Alric L; Duffaut M; Vinel JP; Pascal JP; Puel J; Izopet J
J Virol; 2000 Jan; 74(2):661-8. PubMed ID: 10623727
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and virological response to interferon therapy in patients with chronic hepatitis C, co-infected with hepatitis G virus.
Shibahara N; Moriyama M; Abe K; Tanaka N; Arakawa Y
J Viral Hepat; 2000 Jan; 7(1):43-50. PubMed ID: 10718942
[TBL] [Abstract][Full Text] [Related]
7. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
[TBL] [Abstract][Full Text] [Related]
8. Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4.
Zekri AR; El-Din HM; Bahnassy AA; Khaled MM; Omar A; Fouad I; El-Hefnewi M; Thakeb F; El-Awady M
Virol J; 2007 Feb; 4():16. PubMed ID: 17300723
[TBL] [Abstract][Full Text] [Related]
9. Effect of increasing dose of interferon on the evolution of hepatitis C virus 1b quasispecies.
De Mitri MS; Mele L; Morsica G; Chen CH; Sitia G; Gramenzi A; Andreone P; Alberti A; Bernardi M; Pisi E
J Med Virol; 2000 Feb; 60(2):133-8. PubMed ID: 10596011
[TBL] [Abstract][Full Text] [Related]
10. Early changes in hepatitis C virus (HCV) RNA levels predict response to interferon treatment in noncirrhotic HCV patients.
Fallows G; Kaita K; Minuk G; Penner F; Smart G; Dawood M; Rosser B
Can J Gastroenterol; 2000; 14 Suppl B():30B-35B. PubMed ID: 10938502
[TBL] [Abstract][Full Text] [Related]
11. Lack of clinical significance of variability in the internal ribosome entry site of hepatitis C virus.
Thelu MA; Drouet E; Hilleret MN; Zarski JP
J Med Virol; 2004 Mar; 72(3):396-405. PubMed ID: 14748063
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of hepatitis C virus quasispecies turnover during interferon-alpha treatment.
von Wagner M; Lee JH; Rüster B; Kronenberger B; Sarrazin C; Roth WK; Zeuzem S
J Viral Hepat; 2003 Nov; 10(6):413-22. PubMed ID: 14633173
[TBL] [Abstract][Full Text] [Related]
13. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy.
Pawlotsky JM; Germanidis G; Frainais PO; Bouvier M; Soulier A; Pellerin M; Dhumeaux D
J Virol; 1999 Aug; 73(8):6490-9. PubMed ID: 10400744
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study.
Hino K; Yamaguchi Y; Fujiwara D; Katoh Y; Korenaga M; Okazaki M; Okuda M; Okita K
J Viral Hepat; 2000 Jan; 7(1):36-42. PubMed ID: 10718941
[TBL] [Abstract][Full Text] [Related]
15. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.
Sato M; Maekawa S; Komatsu N; Tatsumi A; Miura M; Muraoka M; Suzuki Y; Amemiya F; Takano S; Fukasawa M; Nakayama Y; Yamaguchi T; Uetake T; Inoue T; Sato T; Sakamoto M; Yamashita A; Moriishi K; Enomoto N
J Virol; 2015 Jun; 89(11):6105-16. PubMed ID: 25810555
[TBL] [Abstract][Full Text] [Related]
16. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
Murphy MD; Rosen HR; Marousek GI; Chou S
Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
[TBL] [Abstract][Full Text] [Related]
17. Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin.
Bukowska-Ośko I; Pawełczyk A; Perlejewski K; Kubisa N; Caraballo Cortés K; Rosińska M; Płoski R; Fic M; Kaźmierczak J; Popiel M; Ząbek P; Horban A; Radkowski M; Laskus T
PLoS One; 2015; 10(5):e0125604. PubMed ID: 25932941
[TBL] [Abstract][Full Text] [Related]
18. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of serum hepatitis C virus load and quasispecies complexity during antiviral therapy in patients with chronic hepatitis C.
Grahovac B; Bingulac-Popovic J; Vucelic B; Hrstic I; Ostojic R; Drazic V; Balija M; Grgicevic D
J Clin Virol; 2001 Jan; 20(1-2):85-9. PubMed ID: 11163588
[TBL] [Abstract][Full Text] [Related]
20. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.
Kieffer TL; Sarrazin C; Miller JS; Welker MW; Forestier N; Reesink HW; Kwong AD; Zeuzem S
Hepatology; 2007 Sep; 46(3):631-9. PubMed ID: 17680654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
